Cogent Biosciences, Inc. Common Stock (COGT)
Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for rare genetic diseases and cancers. The company's research centers on precision medicines that inhibit specific kinases involved in disease pathways, with a particular emphasis on conditions such as systemic mastocytosis and other tumor-related disorders. Founded to leverage insights into kinase biology, Cogent aims to deliver personalized treatment options for patients with limited or no effective therapies.
Company News
Cogent Biosciences plans to raise approximately $200 million through a public offering of 22,222,223 common stock shares at $9.00 per share, with proceeds intended for product development and corporate purposes.
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) fell sharply in today’s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first quarter 2024 financial results. Marinus Pharma report...